These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27605635)

  • 1. Eligibility For And Enrollment In Medicare Part D Medication Therapy Management Programs Varies By Plan Sponsor.
    Stuart B; Hendrick FB; Shen X; Dai M; Tom SE; Dougherty JS; Miller LM
    Health Aff (Millwood); 2016 Sep; 35(9):1572-80. PubMed ID: 27605635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of an integrated adherence program aimed to increase Medicare Part D star rating measures.
    Leslie RS; Tirado B; Patel BV; Rein PJ
    J Manag Care Spec Pharm; 2014 Dec; 20(12):1193-203. PubMed ID: 25443513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare part D: selected issues for plan sponsors, pharmacists, and beneficiaries in 2008.
    Depue R; Stubbings J
    J Manag Care Pharm; 2008; 14(1):50-60. PubMed ID: 18240882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
    Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
    Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
    Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
    J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of pharmacist-provided medication therapy management (MTM) services in community pharmacies over 7 years.
    Barnett MJ; Frank J; Wehring H; Newland B; VonMuenster S; Kumbera P; Halterman T; Perry PJ
    J Manag Care Pharm; 2009; 15(1):18-31. PubMed ID: 19125547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic assessment of changes to an existing medication therapy management program of a large regional health plan.
    Peasah SK; Hammonds T; Liu Y; Campbell V; Manolis C; Good CB
    J Manag Care Spec Pharm; 2021 Feb; 27(2):147-156. PubMed ID: 33506728
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Eligibility Criteria Used to Identify Patients for Medication Therapy Management Services: A Retrospective Cohort Study in a Medicare Advantage Part D Population.
    Lee JS; Yang J; Stockl KM; Lew H; Solow BK
    J Manag Care Spec Pharm; 2016 Jan; 22(1):22-30. PubMed ID: 27015048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare Part D: selected issues for plan sponsors, pharmacists, and beneficiaries in 2009.
    Stubbings J; DePue RJ
    Am J Manag Care; 2009 Sep; 15(9):645-9. PubMed ID: 19747029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare Prescription Drug Plan Enrollees Report Less Positive Experiences Than Their Medicare Advantage Counterparts.
    Elliott MN; Landon BE; Zaslavsky AM; Edwards C; Orr N; Beckett MK; Mallett J; Cleary PD
    Health Aff (Millwood); 2016 Mar; 35(3):456-63. PubMed ID: 26953300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicare Part D: early findings on enrollment and choices for rural beneficiaries.
    McBride TD; Terry TL; Mueller KJ
    Rural Policy Brief; 2006 Apr; 10(8 (PB2006-8)):1-9. PubMed ID: 16685809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of an open enrollment service on costs for Medicare Part D beneficiaries.
    Leonard CE; Cohenour FV; DeLoach LA; Galdo JA
    J Am Pharm Assoc (2003); 2017; 57(3S):S225-S228. PubMed ID: 28412055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
    Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
    J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should eligibility for medication therapy management be based on drug adherence?
    Stuart B; Loh E; Miller L; Roberto P
    J Manag Care Pharm; 2014 Jan; 20(1):66-75. PubMed ID: 24511767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders.
    Donohue JM; Frank RG
    Psychiatr Serv; 2007 Oct; 58(10):1285-91. PubMed ID: 17914004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
    Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
    Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
    Bergeson JG; Worley K; Louder A; Ward M; Graham J
    J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.